Clinical Presentation and Underlying Pathophysiology
The client at
34 weeks gestation presents with a classic triad of severe preeclampsia: critically elevated blood pressure (
170/110 mmHg), cerebral symptoms (severe headache and visual disturbances), and laboratory evidence of end-organ damage (proteinuria
3+, elevated liver enzymes). This clinical picture indicates a state of widespread maternal endothelial dysfunction and vasospasm, which has now progressed to central nervous system (CNS) irritability. The severe headache and visual disturbances are not merely discomfort; they are prodromal signs of cortical irritability and cerebral edema, signaling a high imminent risk for seizure activity, known as eclampsia.
Priority Nursing Intervention: Rationale for Seizure Precautions
The priority intervention is to implement seizure precautions and maintain a quiet, dimly lit environment. In the hierarchy of maternal care for severe preeclampsia, the prevention of eclamptic seizures is paramount because an eclamptic seizure leads to severe maternal hypoxia, trauma, and can precipitate placental abruption, fetal distress, and maternal death. The foundational pharmacologic agent for this prevention is
magnesium sulfate. Evidence confirms that magnesium sulfate is the drug of choice for the prevention and treatment of eclampsia, acting as a cornerstone therapy to reduce the risk of severe morbidity and mortality for the woman and her baby [1, 2]. The nursing action of creating a quiet, dimly lit environment directly complements this pharmacologic strategy by minimizing external sensory stimuli (photophobia, phonophobia) that can trigger seizure activity in an already hyper-excitable CNS.
Analysis of Other Options in the Context of Immediate Priority
While the other listed interventions are all necessary components of care, they do not take precedence over immediate seizure prophylaxis.
- Administering prescribed antihypertensive medication (Option 1) is critical to prevent maternal intracranial hemorrhage, but it does not directly address the underlying CNS irritability that leads to eclampsia. Blood pressure control and seizure prevention are parallel, emergent goals, but the primary pharmacologic agent for the latter, magnesium sulfate, must be initiated without delay
[2].
- Preparing for immediate cesarean delivery (Option 2) is the definitive treatment for preeclampsia, but delivery is not the immediate priority in an unstable, pre-seizure state. The maternal condition must first be stabilized with magnesium sulfate to prevent intraoperative or immediate postoperative seizures, which would be catastrophic
[1].
- Inserting an indwelling urinary catheter (Option 4) is essential for strict intake and output monitoring, especially given the risk of oliguria and the need to monitor for magnesium sulfate toxicity, as the drug is renally excreted. However, this is a secondary intervention that follows the initial stabilization and initiation of seizure precautions and magnesium sulfate therapy
[2].
Integrating Pharmacology into Nursing Action
The nursing intervention of "implementing seizure precautions" is inseparable from the preparation for and administration of
magnesium sulfate. The therapeutic window of magnesium sulfate is narrow, and its use in practice can be heterogeneous
[2]. The nurse’s role extends beyond hanging the intravenous medication; it includes establishing safety measures (padded side rails, oxygen and suction equipment at the bedside) and performing continuous clinical monitoring for therapeutic effect, loss of deep tendon reflexes, respiratory depression, and cardiac function, all of which are components of comprehensive seizure precautions grounded in the drug's pharmacology and mechanisms of action
[2].
References (research sources)
- [1]
Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia.Research articleDiaz V, Long Q, Oladapo OT. (2023) · DOI: 10.1002/14651858.cd007388.pub3
- [2]
Magnesium sulfate pharmacology for maternal and critical-care indications: mechanisms, pharmacokinetics, and the therapeutic window.Research articleXia M, Ni Q, Zhu S. (2026) · DOI: 10.3389/fphar.2026.1749828